Building on its R&D reorganisation efforts, Sanofi has signed a multi-year collaboration agreement with Nurix Therapeutics to discover, develop and commercialise a pipeline of targeted protein degradation drugs across multiple therapeutic areas. The deal, worth up to US$2.6 B, allows Nurix to utilise its platform to discover novel drug candidates by manipulating E3 ligases which holds potential in multiple diseases.